Return to study ST001704 main page
MB Sample ID: SA158417
| Local Sample ID: | posMSMSALL-SC-D3-IR_SA123_1 |
| Subject ID: | SU001781 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | C57BL/6J |
| Age Or Age Range: | 12-17 weeks |
| Gender: | Female |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU001781 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | C57BL/6J |
| Age Or Age Range: | 12-17 weeks |
| Gender: | Female |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| posMSMSALL-SC-D3-IR_SA123_1 | SA158417 | FL018504 | Non-IR Control | Treatment |
Collection:
| Collection ID: | CO001774 |
| Collection Summary: | Lipidomic analyses were performed on mouse serum (n=3) collected through submandibular and terminal blood collections. Blood samples were extracted (10% of total body weight) and allowed to clot for 60 minutes at room temperature at which point the samples were centrifuged for 15 minutes at 12,000 RCF. The upper phase containing serum was transferred to a new, sterile microcentrifuge tube and frozen at -80°C. |
| Sample Type: | Blood (serum) |
| Collection Method: | submandibular and terminal blood collection |
| Collection Frequency: | Day 3 and Day 35 |
| Storage Conditions: | -80℃ |
| Collection Vials: | sterile microcentrifuge tube |
| Storage Vials: | sterile microcentrifuge tube |
Treatment:
| Treatment ID: | TR001794 |
| Treatment Summary: | Forty female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA), 12 weeks of age, were randomly split between two cohorts; Irradiated (IR) and Non-Irradiated (Non-IR) (n=20) and were used for all experiments. Two sub-lethal doses of cesium-137 (Cs-137) whole-body irradiation (2x 3 Gy; total of 6 Gy) with an exposure time of 3.72 minutes per mouse (total of 7.44 minutes) were administered 4 hours apart to the IR mice (n=20) on Day 0. Within each cohort, mice were sub-divided into treatment groups; Vehicle and Scl-Ab VI (25 mg/kg) (supplied by Amgen Inc/UCB Pharma) (n=10/per treatment). All mice were administered either a sterile phosphate buffered saline (PBS) vehicle control or Scl-Ab (25 mg/kg), once weekly via subcutaneous injections for a duration of 5 weeks, starting on Day 0. No adverse effects were observed after the administration of Scl-Ab. All experimental studies and procedures involving mice were performed in accordance with protocols approved by the governing Institutional Animal Care and Use Committee (IACUC). Additional Study Design and Drug Treatment information can be found in the Supplemental Material. |
| Treatment: | Neutralizing antibodies to sclerostin (Scl-Ab) |
| Treatment Compound: | Scl-Ab VI (supplied by Amgen Inc/UCB Pharma) |
| Treatment Route: | subcutaneous injections |
| Treatment Dose: | 25 mg/kg |
| Treatment Doseduration: | once weekly for 5 weeks |
| Treatment Vehicle: | sterile phosphate buffered saline (PBS) vehicle control |
Sample Preparation:
| Sampleprep ID: | SP001787 |
| Sampleprep Summary: | Three 12 µL serum aliquots per treatment (representative of individual mice) were provided to the MMCRI Proteomics and Lipidomics Core Facility for analysis. The individual samples were sub-divided into technical replicates, which were then averaged together. Lipid extracts were dissolved in methanol/dichloromethane for mass spectrometry (MS) analysis. Lipidomic analyses were completed via 5600 TripleTOF mass spectrometer (Sciex, Framingham, MA) and downstream analyses, including t-tests and principal component analyses (PCAs), were completed utilizing MarkerView Software (Sciex). PCAs were performed with no weighting, Pareto scaling, and supervised data analysis. Lipids were analyzed using a global, bias-free lipid profiling acquisition technique (MS/MSALL). |
| Processing Storage Conditions: | -80℃ |
| Extract Storage: | -80℃ |
Combined analysis:
| Analysis ID | AN002775 | AN002776 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | None (Direct infusion) | None (Direct infusion) |
| Chromatography system | Sciex TripleTOF 5600 | Sciex TripleTOF 5600 |
| Column | none | none |
| MS Type | ESI | ESI |
| MS instrument type | QTOF | QTOF |
| MS instrument name | ABI Sciex 5600 TripleTOF | ABI Sciex 5600 TripleTOF |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | m/z | m/z |
Chromatography:
| Chromatography ID: | CH002055 |
| Chromatography Summary: | Direct infusion |
| Instrument Name: | Sciex TripleTOF 5600 |
| Column Name: | none |
| Chromatography Type: | None (Direct infusion) |
MS:
| MS ID: | MS002572 |
| Analysis ID: | AN002775 |
| Instrument Name: | ABI Sciex 5600 TripleTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Direct infusion positive and negative mode MSMSALL workflow Sciex-LipidView; Sciex-MarkerView |
| Ion Mode: | POSITIVE |
| MS ID: | MS002573 |
| Analysis ID: | AN002776 |
| Instrument Name: | ABI Sciex 5600 TripleTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Direct infusion positive and negative mode MSMSALL workflow Sciex-LipidView; Sciex-MarkerView |
| Ion Mode: | NEGATIVE |
